Challenge
A leading UK university and an executive agency of the DoH were collaboratively developing a rapid (30 min) bacterial ID and antimicrobial resistance test platform. The technology represented a promising approach to developing simple, rapid bacterial and AMR tests with aspirations to be performed in near-patient settings. The project was relatively early stage, with proof of concept of bacterial ID only demonstrated at the time. Sensitivity and performance in clinical samples was yet to be determined, and a patent filing was underway. Alacrita was asked to produce a commercial development plan and valuation for the technology.
Solution
We identified activities and highlighted milestones, risks and budgets in order to reach key inflection points. We held a briefing meeting with the inventor in order to access any technical or commercial updates to the project, its status, key results/data, project plans, any available vendor budgets or quotations, etc. We supplemented this with secondary research and selected interviews with our established industry contacts and our in-house knowledge and experience, in order to compile a robust valuation of the program based on the opportunity and the most likely path to market.
Opportunity Mapping Services
We can help you gauge and rank the opportunities for your R&D programs or technology platforms to deliver value, by framing the commercial potential and charting the path to market.
Back